Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Single Arm Study to Evaluate the Efficacy and Safety of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Conditions
Interventions
Mogamulizumab
Locations
8
China
Peking University First Hospital, Department of Dermatology and Venereology
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center, Department of Medical Oncology
Guangzhou, Guangdong, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Start Date
May 29, 2023
Primary Completion Date
August 12, 2025
Completion Date
November 13, 2025
Last Updated
September 18, 2025
NCT06588868
NCT05333367
NCT04128072
NCT04072458
NCT04745234
NCT04362007
Lead Sponsor
Kyowa Kirin China Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions